New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not …
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC